If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
7 December 2020 Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
13 August 2020 Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.
14 May 2020 Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
7 December 2020 Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
13 August 2020 Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.
14 May 2020 Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
7 December 2020 Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
13 August 2020 Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.
14 May 2020 Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
